Arpan Bhattacharyya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arpan Bhattacharyya has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Benu Brata Das
Laboratory of Molecular Biology, School of Biological Sciences, Indian Association for the Cultivation of Science, 2A & B, Raja S. C. Mullick Road, Jadavpur, Kolkata 700032, India
2 shared publications Anirban Ghosh
School of Materials Sciences, Indian Association for the Cultivation of Science, 2A & 2B Raja S. C. Mullick Road, Jadavpur, Kolkata 700 032, India
1 shared publicationArijit Ghosh
Laboratory of Molecular Biology, School of Biological Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata–700 032, India
1 shared publication- Asim Bhaumik
School of Materials Sciences Indian Association for the Cultivation of Science Kolkata India
1 shared publication Dipak Datta
Division of Cancer Biology, Council of Scientific and Industrial Research-Central Drug Research Institute, Lucknow 226031, India
1 shared publication- Laura Baranello
Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 20 May 2026
- Vol. 54 (10)
Arginine methylation of human DNA topoisomerase I by PRMT5 facilitates DNA relaxation.
DNA topoisomerase 1 (Top1) is essential for resolving DNA supercoiling during replication and transcription. Here, we identify protein arginine methyltransferase 5 (PRMT5) as a novel regulator of human Top1 activity via symmetric dimethylation at arginine residues R708 and R749, located in the linker and catalytic domains, respectively. Methylation enhances Top1-mediated strand rotation and DNA relaxation without affecting its DNA binding ability. In contrast, methylation-deficient Top1 mutants (Top1KK) display impaired subnuclear mobility and accumulate elevated levels of trapped Top1-DNA covalent complexes (Top1cc) upon camptothecin (CPT) treatment. These defects are independent of PRMT5-Top1 binding but are dependent on PRMT5's enzymatic activity. Loss of Top1 methylation-via point mutation, PRMT5 knockout, or pharmacological inhibition-delays Top1cc resolution and amplifies CPT-induced DNA damage. Strikingly, combining PRMT5 inhibitors (PRMT5i) with Top1 poisons such as irinotecan enhances cytotoxicity across multiple cancer cell types. In a triple-negative breast cancer mouse model, this combination significantly suppresses tumor growth and metastasis, accompanied by increased DNA damage. Our results define PRMT5-driven Top1 arginine methylation as a crucial regulatory mechanism and highlight PRMT5i as a means to potentiate Top1-based cancer treatment.
- 20 May 2026
- Vol. 54 (10)
Open AccessArginine methylation of human DNA topoisomerase I by PRMT5 facilitates DNA relaxation.
DNA topoisomerase 1 (Top1) is essential for resolving DNA supercoiling during replication and transcription. Here, we identify protein arginine methyltransferase 5 (PRMT5) as a novel regulator of human Top1 activity via symmetric dimethylation at arginine residues R708 and R749, located in the linker and catalytic domains, respectively. Methylation enhances Top1-mediated strand rotation and DNA relaxation without affecting its DNA binding ability. In contrast, methylation-deficient Top1 mutants (Top1KK) display impaired subnuclear mobility and accumulate elevated levels of trapped Top1-DNA covalent complexes (Top1cc) upon camptothecin (CPT) treatment. These defects are independent of PRMT5-Top1 binding but are dependent on PRMT5's enzymatic activity. Loss of Top1 methylation-via point mutation, PRMT5 knockout, or pharmacological inhibition-delays Top1cc resolution and amplifies CPT-induced DNA damage. Strikingly, combining PRMT5 inhibitors (PRMT5i) with Top1 poisons such as irinotecan enhances cytotoxicity across multiple cancer cell types. In a triple-negative breast cancer mouse model, this combination significantly suppresses tumor growth and metastasis, accompanied by increased DNA damage. Our results define PRMT5-driven Top1 arginine methylation as a crucial regulatory mechanism and highlight PRMT5i as a means to potentiate Top1-based cancer treatment.
- 11 January 2024
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 53 (7) , 3010-3019
Mitochondrial topoisomerase 1 targeted anticancer therapy using irinotecan encapsulated mesoporous MIL-101(Fe) synthesized via a vapour assisted method
MOF-mediated selective delivery of irinotecan into the mitochondria to trap mitochondrial Top1-covalent complexes for anticancer chemotherapy.
- 11 January 2024
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 53 (7) , 3010-3019
Mitochondrial topoisomerase 1 targeted anticancer therapy using irinotecan encapsulated mesoporous MIL-101(Fe) synthesized via a vapour assisted method
MOF-mediated selective delivery of irinotecan into the mitochondria to trap mitochondrial Top1-covalent complexes for anticancer chemotherapy.